- SEK2.01bn
- SEK1.43bn
Brief: Flerie Holds 43.59% Of Shares In Nanologica
Brief: Nanologica Board Recommends Not To Accept Cash Offer Made By Flerie Invest
Brief: Flerie Portfolio Company Receives First U.S. Order
Brief: Flerie Invest Announces Mandatory Cash Offer To Shareholders Of Nanologica
Brief: Flerie, Toleranzia General Meetings Approve Merger Plan
Brief: Flerie Jan-March NAV SEK 3,947 Million
Brief: Flerie's Lipum Presents Final Results From Phase I Trial Of Sol-116
Brief: Flerie Sells Toleranzia Shares To Long-Term Flerie Investors
Brief: Flerie's Unit Provell Pharmaceuticals Files For Bankruptcy Under Chapter 7 In U.S.
Brief: Flerie's NAV Per Share At SEK 50.56
Brief: Toleranzia Recommends Shareholders To Vote For Merger With Flerie
Brief: Flerie And Toleranzia Agree On Merger Plan To Take Toleranzia Private
Brief: Flerie Divests Shares In A3P Biomedical For SEK 71.3 Mlm
Brief: Flerie Q4 Net Loss SEK 64 Million
Brief: Flerie: Anacardio Reports Results Of Phase 1B Study Of AC01
Brief: Flerie Q3 Net Asset Value Rises To SEK 4.26 Bln
Brief: Flerie Purchased Shares In Xspray Pharma For Approx. Sek 5.6 Mln
Brief: Alligator Bioscience Appoints Johan Giléus As CFO
Brief: Flerie Explores Conditions For Directed Issue